Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients

Table 1 AR mutations detected in CRPC patients

Patient	Amino acid change	Mutant read count	Wild-type read count	Total read count	Percent mutant
VC-001-t1*	T878A	39	13,231	13,270	0.29
	H875Y	36	13,351	13,387	0.27
	H875Y/T878A	251	13,019	13,270	1.89
VC-001-t2	T878A	30	12,626	12,656	0.24
	H875Y	0	13,307	13,307	0.00
	H875Y/T878A	230	12,426	12,656	1.82
	T878A/D891H	158	10,383	10,541	1.50
	D891H	8	10,533	10,541	0.08
VC-005	E894K	170	10,745	10,915	1.56
VC-012-t1	M896V	1,270	5,985	7,255	17.51
VC-012-t1*	S889G	307	4,769	5,076	6.05
	M896V	273	5,838	6,111	4.47
VC-012-t2	S889G	103	8,202	8,305	1.24
	M896V	31	8,934	8,965	0.35
	H875Y	49	10,355	10,404	0.47
	T878A	300	9,760	10,060	2.98
	F877L/T878A	141	9,919	10,060	1.40
	T878A/S889G	35	8,270	8,305	0.42
VC-014*	E898G	237	11,919	12,156	1.95
VC-015	T878A	218	9,502	9,720	2.24
VC-017	T878A	99	12,626	12,725	0.78
VC-018*	H875Y	223	10,382	10,605	2.10
VC-021*	H875Q	251	9,846	10,097	2.49
VC-021*	T919S	238	9,004	9,242	2.58
VC-022	D880E	12	10,902	10,914	0.11
VC-040	H875Y	479	7,560	8,039	5.96
VC-041-t1	H875Y	1,521	7,260	8,781	17.32
VC-041-t2	H875Y	4,665	15,662	20,327	22.95
VC-053	H875Y	136	9,064	9,200	1.48
VC-063	H875Y	270	14,874	15,144	1.78
VC-064	L882I	17	15,670	15,687	0.11

Newly reported samples sequenced from WGA2 DNA are marked with a *. Each horizontal line in the table represents a particular haplotype, hence multiple lines for some data points. Only patients with mutations detected in cfDNA or in WGA2 cfDNA are shown

ISSN: 1474-760X